Arthur Kavanaugh

19.7k citations

195 papers · 11.4k indexed · 6 hit papers · h-index 44

Impact in

Rheumatology top 0.02%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
Hematology top 0.1%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 172
- Rheumatoid Arthritis Research and Therapies 159
- Systemic Lupus Erythematosus Research 55
- Spondyloarthritis Studies and Treatments 33
Hematology 68
- Autoimmune and Inflammatory Disorders Research 66

Co-authors: Paul Emery Iain B. McInnes Daniel H. Solomon Vibeke Strand Gerd R Burmester Gary S. Firestein Ronald van Vollenhoven Daniel Aletaha
Journals: Annals of the Rheumatic Diseases (54 papers)The Journal of Rheumatology (15 papers)Lara D. Veeken (11 papers)Arthritis Research & Therapy (5 papers)Current Opinion in Rheumatology (5 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Arthur Kavanaugh

190 papers receiving 11.1k citations

Hit Papers

6 papers align trajectories log scale

Rheumatoid arthritis 2018 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Reviews Disease Primers
2015 New England Journal of Medicine
2013 The Lancet
2009 Arthritis & Rheumatism
2006 Arthritis & Rheumatism
2005 Annals of the Rheumatic Diseases

Peers

Countries citing papers authored by Arthur Kavanaugh

Since Specialization

Citations

This map shows the geographic impact of Arthur Kavanaugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Kavanaugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Kavanaugh more than expected).

Fields of papers citing papers by Arthur Kavanaugh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Kavanaugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Kavanaugh. The network helps show where Arthur Kavanaugh may publish in the future.

Co-authors

The 25 scholars most cited alongside Arthur Kavanaugh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur Kavanaugh Line = papers co-authored together Arthur Kavanaugh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial Nature Medicine ·Iain B. McInnes, Laura C. Coates, Philip J. Mease, Alexis Ogdie, Arthur Kavanaugh, Lihi Eder, Georg Schett, Alan Kivitz, Dennis McGonagle, Nuala Brennan, A. Godwood, Eva Cullen, Kristian Reich, Christopher T. Ritchlin, Joseph F. Merola	2025	1
2	Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial Lara D. Veeken ·Arthur Kavanaugh, Laura C. Coates, Philip J. Mease, Miroslawa Nowak, Lauren Hippeli, Thomas Lehman, Subhashis Banerjee, Joseph F. Merola	2024	3
3	Impact of filgotinib on pain control in the phase 3 FINCH studies RMD Open ·Peter C. Taylor, Arthur Kavanaugh, Peter Nash, Janet Pope, Georg Pongratz, Bruno Fautrel, Rieke Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens	2024	5
4	Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels : Results from a Phase 3 Clinical Study Arthritis & Rheumatism ·D. van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, D. Graham, C.S. Wang, Lara Fallon	2017	1
5	Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials Queensland's institutional digital repository (The University of Queensland) ·Philip J. Mease, Dafna D. Gladman, Arthur Kavanaugh, Priscila Nakasato, B. Guérette, Lichen Teng, Peter Nash	2017	1
6	Alterations in immune function with biologic therapies for autoimmune disease Journal of Allergy and Clinical Immunology ·Minyoung Her, Arthur Kavanaugh	2016	97
7	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics Arthritis Research & Therapy ·Glynn Dennis, Cécile Holweg, Sarah Kummerfeld, David F. Choy, Audi Setiadi, Jason A. Hackney, Peter M. Haverty, Houston Gilbert, Wei Lin, Lauri Diehl, Sven Fischer, An Song, David Musselman, Micki Klearman, Cem Gabay, Arthur Kavanaugh, Judith Endres, David A. Fox, Flavius Martin, Michael J. Townsend	2014	265
8	Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Data Archiving and Networked Services (DANS) ·Philip Mease, Iain B. McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan, Hanno B. Richards, Shephard Mpofu	2014	12
9	Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial Queensland's institutional digital repository (The University of Queensland) ·Alice B. Gottlieb, Philip Mease, Iain B. McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Peter Nash, Luminita Pricop, Jiacheng Yuan, Hanno B. Richards, Shephard Mpofu	2014	12
10	Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study The Journal of Rheumatology ·Josef S Smolen, van Vollenhoven, Arthur Kavanaugh, Vibeke Strand, Jiří Vencovský, Michael Schiff, Robert Landewé, Boulos Haraoui, Samantha Walker, van der Heijde	2013	1
11	Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial Data Archiving and Networked Services (DANS) ·E C Keystone, F. C. Breedveld, D. van der Heijde, Robert Landewé, S. Florentinus, Udayasankar Arulmani, S.F. Liu, H. Küpper, Arthur Kavanaugh	2013	1
12	Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate Data Archiving and Networked Services (DANS) ·M. Weinblatt, Mark C. Genovese, M. Ho, Scott Hollis, Krystyna Rosiak‐Jedrychowicz, Arthur Kavanaugh, David Millson, G. Léon, M. Wang, D. van der Heijde	2013	7
13	Treat-to-Target in Rheumatoid Arthritis: Clinical and PharmacoEconomic Considerations Clinical and Experimental Rheumatology ·Ariel Béresniak, Jürgen Braun, Paolo Angelo Cortesi, Gianfranco Ferraccioli, Merete Lund Hetland, Johannes W G Jacobs, Arthur Kavanaugh, Raashid Luqmani, Marta Mosca, Theodore Pincus, Duncan Porter, Vappu Rantalaiho, Angelo Ravelli, David L. Scott, Josef S Smolen, Christian Thielscher, Giuseppe Turchetti, Marianne van den Broek, Yusuf Yazıcı	2012	3
14	Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure Research Explorer (The University of Manchester) ·Arthur Kavanaugh, Michael E. Weinblatt, Mark C. Genovese, Theresa K. Musser, Elliott B. Grossbard, Daniel B. Magilavy, Sally Hollis	2011	7
15	Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial Data Archiving and Networked Services (DANS) ·Edward Keystone, D. van der Heijde, M. Weinblatt, Neelufar Mozaffarian, B. Guérette, H. Küpper, S.F. Liu, B M Wolfe, Arthur Kavanaugh	2011	1
16	Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial Data Archiving and Networked Services (DANS) ·F. C. Breedveld, Edward Keystone, D. van der Heijde, Robert Landewé, J S Smolen, B. Guérette, M. McIlraith, H. Küpper, S.F. Liu, B M Wolfe, Arthur Kavanaugh	2011	5
17	EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS : 3-YEAR DATA FROM THE RAPID 2 STUDY Lara D. Veeken ·Josef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, Andreas Fichtner, Vibeke Strand, Jiří Vencovský, D. van der Heijde	2011	2
18	Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study BMC Musculoskeletal Disorders ·Mari Hoff, Tore K. Kvien, Johan Kälvesten, Aake Elden, Arthur Kavanaugh, Glenn Haugeberg	2011	41
19	GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY Lara D. Veeken ·Arthur Kavanaugh, D. van der Heijde, C. Chattopadhyay, D. Gladman, P.J. Mease, Iain B. McInnes, G.G. Krueger, W. Xu, Mahboob U. Rahman, Julie Zrubek, Anna Baratelle, Anna Beutler, Go-Reveal Investigators	2010	9
20	The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. PubMed ·PE Lipsky, Arthur Kavanaugh	1999	13

About Arthur Kavanaugh

Arthur Kavanaugh is a scholar working on Rheumatology, Hematology, Genetics, Immunology and Pathology and Forensic Medicine, having authored 195 papers that have together received 11.4k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (159 papers), Autoimmune and Inflammatory Disorders Research (66 papers), Systemic Lupus Erythematosus Research (55 papers), Chronic Lymphocytic Leukemia Research (33 papers), Spondyloarthritis Studies and Treatments (33 papers), Lymphoma Diagnosis and Treatment (30 papers), Biosimilars and Bioanalytical Methods (24 papers) and Psoriasis: Treatment and Pathogenesis (18 papers). The work is most often cited by research in Rheumatology (7.6k citations), Hematology (3.5k citations), Immunology (4.1k citations), Genetics (1.5k citations) and Pathology and Forensic Medicine (1.2k citations). Arthur Kavanaugh has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Paul Emery, Iain B. McInnes, Daniel H. Solomon, Vibeke Strand, Gerd R Burmester, Gary S. Firestein, Ronald van Vollenhoven, Daniel Aletaha, Josef S Smolen and Anne Barton. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Lara D. Veeken, Arthritis Research & Therapy and Current Opinion in Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact